Detection of astrocytic tau pathology facilitates recognition of chronic traumatic encephalopathy neuropathologic change

Kamar E. Ameen-Ali1, Abigail Bretzin2, Edward B. Lee3, Rebecca Folkerth4,5, Lili-Naz Hazrati6,7, Diego Iacono8,9,10,11,12, C. Dirk Keene13, Julia Kofler14, Gabor G. Kovacs15,16, Amber Nolan13, Daniel P. Perl8,9, David S. Priemer8,9,12, Douglas H. Smith17, Douglas J. Wiebe2, William Stewart1,18* and CONNECT-TBI Investigators

Abstract

Traumatic brain injury (TBI) is associated with the development of a range of neurodegenerative pathologies, including chronic traumatic encephalopathy (CTE). Current consensus diagnostic criteria define the pathognomonic cortical lesion of CTE neuropathologic change (CTE-NC) as a patchy deposition of hyperphosphorylated tau in neurons, with or without glial tau in thorn-shaped astrocytes, typically towards the depths of sulci and clustered around small blood vessels. Nevertheless, although incorporated into consensus diagnostic criteria, the contribution of the individual cellular components to identification of CTE-NC has not been formally evaluated. To address this, from the Glasgow TBI Archive, cortical tissue blocks were selected from consecutive brain donations from contact sports athletes in which there was known to be either CTE-NC (n = 12) or Alzheimer’s disease neuropathologic change (n = 4). From these tissue blocks, adjacent tissue sections were stained for tau antibodies selected to reveal either solely neuronal pathology (3R tau; GT-38) or mixed neuronal and astroglial pathologies (4R tau; PHF-1). These stained sections were then randomised and independently assessed by a panel of expert neuropathologists, blind to patient clinical history and primary antibody applied to each section, who were asked to record whether CTE-NC was present. Results demonstrate that, in sections stained for either 4R tau or PHF-1, consensus recognition of CTE-NC was high. In contrast, recognition of CTE-NC in sections stained for 3R tau or GT-38 was poor; in the former no better than chance. Our observations demonstrate that the presence of both neuronal and astroglial tau pathologies facilitates detection of CTE-NC, with its detection less consistent when neuronal tau pathology alone is visible. The combination of both glial and neuronal pathologies, therefore, may be required for detection of CTE-NC.

Keywords: Chronic traumatic encephalopathy, Traumatic brain injury, Neurodegeneration, Tau, Aging-related tau astrogliopathy

Introduction

Increased risk of neurodegenerative disease has long been recognized following exposure to traumatic brain injury (TBI), with an estimated 3–10% of dementia in the community thought to be influenced by prior exposure to TBI [33, 43]. While a range of clinical syndromes and associated neuropathologies are described among late survivors of TBI [15, 22, 23, 26, 35, 47], there has been...
particular interest paid to the specific TBI associated
pathology of chronic traumatic encephalopathy (CTE)
[36, 45, 46]. Nevertheless, although the neuropathology
of CTE was first described many decades ago, formal
consensus criteria for its neuropathological evaluation
and identification only emerged in the last decade as pro-
visional consensus criteria [37], which have since been
refined [4]. These criteria currently define the pathogno-
monic lesion of CTE neuropathologic change (CTE-NC)
as a patchy cortical deposition of hyperphosphorylated
tau (p-tau) in neurons, with or without glial tau in thorn-
shaped astrocytes, typically clustered around blood ves-
sels towards the depths of sulci [4]. Notably, however,
although incorporated into consensus diagnostic crite-
ria, the contribution of the individual cellular compo-
ments to identification of CTE-NC has not been formally
evaluated.

Following clinical descriptions of the punch drunk
syndrome of former boxers early in the last century [34],
the neuropathology of CTE, then described as demen-
tia pugilistica, emerged several decades later in isolated
case reports and short case series, again largely in for-
mer boxers [3, 7, 12, 17]. In these early accounts a range
of neuropathological abnormalities was noted, including
abundant neurofibrillary tangles [7, 12, 17] and amyloid-
beta pathologies, the latter typically as diffuse plaques
[41]. Of these, the presence of neurofibrillary tangles has
attracted most attention, with early reports suggesting
their distinctive cortical distribution might help to dis-
tinguish CTE from wider neurodegenerative pathologies.
Specifically, neurofibrillary tangles in CTE were typically
described as localised to more superficial cortical layers,
often clustered around small blood vessels and with an
impression that these may show particular concentra-
tion towards the depths of cortical sulci [12, 17]. Notably,
while many of these observations have been incorpo-
rated into consensus criteria defining the pathognomonic
lesion of CTE-NC, when subject to scrutiny, the impres-
sion of specific concentration of neurofibrillary tangles to
sulcal depths appears less distinctive. Thus, using formal
quantitative methodologies, neurofibrillary tangles in
CTE show only a mild increase in density towards sulcal
depths, mirroring that seen in Alzheimer’s disease neuro-
pathologic change (ADNC) [1]. Further, although limited
cryo-electron microscopy observations suggest the tau
filament structure in CTE might differ from that of Alz-
heimer’s disease [9], the immunophenotype of the neu-
ronal pathology in CTE appears indistinguishable from
that of aging and ADNC, using currently available anti-

While p-tau immunoreactive neuronal profiles have
long been recognised, only more recently have p-tau
astrogial pathologies been documented in the context
of aging and neurodegenerative disease [5, 27–30], with
p-tau immunoreactive, thorn-shaped astrocytes rec-
ognised as a prominent component of the pathology of
CTE-NC [20, 21, 25, 36, 38, 42]. Notably, although the
thorn-shaped astrocytes of CTE-NC show comparable
morphology and immunophenotype to those encoun-
tered in aging-related tau astrogliopathy (ARTAG) [2],
quantitative assessment demonstrates this astrocytic
pathology shows preferential concentrates at the depths
of cortical sulci [1]. As such, while recent refinement to
consensus neuropathological criteria proposes that the
presence of p-tau immunoreactive astrocytes is no longer
required for recognition of the pathognomonic lesion of
CTE-NC [4], available evidence might suggest that their
presence may still have some role in differentiating CTE
from other neurodegenerative pathologies.

In this context, we hypothesise that, in routine diagno-
sic practice, the presence of both neuronal and astroglial
tau pathologies is required for optimal detection of CTE-
NC, with its detection less consistent when neuronal tau
pathology alone is present. To this end, using antibodies
that detect either neuronal tau pathology alone or that
detect both neuronal and astroglial pathologies we per-
formed blinded, multi-reviewer, unbiased assessments of
cortical p-tau pathologies in material from former con-
tact sports athletes either with known CTE-NC or with
ADNC. Our observations suggest the presence of both
neuronal and astroglial tau pathologies facilitates detect-
tion of CTE-NC, with its detection less consistent when
neuronal tau pathology alone is visible. Further, in cases
with overwhelming cortical p-tau pathologies, applica-
tion of a combination of tau antibodies might enhance
detection of CTE-NC.

Methods
All cases were obtained from the Glasgow TBI Archive,
Queen Elizabeth University Hospital, Glasgow, UK.
Brain tissue samples were acquired at routine diagno-
sic autopsy, with approval for research tissue donation
and use in research provided by the West of Scotland
Research Ethics Committee (17/WS/0164) and the
Greater Glasgow and Clyde Biorepository (Applica-
tion Number 340). Donors for inclusion in this study
were identified within the database of the Glasgow TBI
Archive by an independent researcher not involved in
reviews of the pathology. Donors were selected as con-
secutive research brain donations from former contact
sports athletes (soccer n = 13; rugby union n = 2; rugby
union and boxing n = 1) with neurodegenerative disease
diagnoses in life, where the original diagnostic neuropa-
thology evaluation documented the presence in corti-
cal sections of either the pathognomonic pathology of
CTE-NC (n = 12) or ADNC (n = 4) by current consensus
criteria \[4, 19, 37, 39\]. Clinical, demographic and neuropathological information, including integrated clinicopathological diagnoses \[32\] are presented in Table 1.

**Immunohistochemistry**

At the time of the original diagnostic autopsy, whole brains were immersion fixed in 10% formal saline for a minimum of two weeks, following which the specimens were examined, sampled using standardised techniques consistent with consensus protocols \[4, 37\] and processed to paraffin tissue blocks as previously described \[13\]. From each case a cortical tissue block documented by the original reporting pathologist (WS) during diagnostic evaluation as containing representative neuropathological features was selected and stained for a panel of antibodies to different tau species. Sections were cut at 8 μm using a rotary microtome (Leica Microsystems, Wetzlar, Germany) and mounted onto Superfrost Plus microscope slides (Cellpath, Powys, UK), before deparaffinisation and rehydration to water and immersion in 3% aqueous hydrogen peroxide for 15 min to quench endogenous peroxidase activity. After washing, microwave pressure cooker heat-mediated antigen retrieval was performed for each antibody using either 0.1 M Tris ethylenediaminetetraacetic acid (EDTA) buffer (pH8) or citrate buffer (pH6), with or without formic acid pre-treatment. Sections were then blocked for 30 min using normal horse serum (Vector Labs, Burlingame, CA, USA), before incubation in the primary antibody at 4 °C for 20 h. Specifically, a panel of tau antibodies was applied targeting either: phosphoepitope S404 (PHF-1; 1:1000; courtesy Dr P Davies); Alzheimer’s conformation dependent tau (GT-38; 1:1000; University of Pennsylvania); or 3 (RD3; 1:3000; Merck Millipore, Germany) or 4 (RD4; 1:400; Merck Millipore, Germany) microtubule-binding domain repeats. Following incubation in primary antibody, sections were rinsed before incubation in a biotinylated universal secondary antibody (Vector Labs, Burlingame, CA, USA) for 30 min at room temperature. Antibody binding was visualised using a 3,3’-diaminobenzidine (DAB) peroxidase substrate kit (Vector Labs, Burlingame, CA, USA). Sections were then counterstained with haematoxylin, followed by rinsing, dehydreation and coverslipping. Sections from a known positive control for each antibody were stained in parallel with test sections, with omission of the primary antibody in one section to control for non-specific binding.

**Whole slide scanning and assessment**

On completion of staining, all 64 stained section (16 cases, each stained with four different antibodies) were scanned with a 20× objective on a Hamamatsu Nanozoomer 2.0-HT slide scanner and saved as NDPI files. File order was then randomised and each file assigned a unique identifying number such that scanned images from each case were neither consecutive in sequence or in number on the slide viewing portal. Slides were

| Case | Age at death | Sex | Sport exposure | PMI (days) | Pathology | CTE-NC Stage | Integrated CPC diagnosis |
|------|--------------|-----|----------------|-----------|-----------|--------------|--------------------------|
| 1    | 70s          | M   | Rugby         | 2         | CTE-NC    | low          | AD                       |
| 2    | 80s          | M   | Soccer        | 1         | CTE-NC    | low          | AD                       |
| 3    | 70s          | M   | Rugby         | 0.5       | CTE-NC    | high         | CTE                      |
| 4    | 70s          | M   | Soccer        | 8         | CTE-NC    | high         | DLB                      |
| 5    | 80s          | M   | Soccer        | 1         | CTE-NC    | high         | PDD                      |
| 6    | 70s          | M   | Soccer        | 3         | CTE-NC    | high         | CTE                      |
| 7    | 60s          | M   | Soccer        | 11        | CTE-NC    | high         | VaD                      |
| 8    | 80s          | M   | Soccer        | 3         | CTE-NC    | high         | CTE                      |
| 9    | 90s          | M   | Rugby/Boxing  | 5         | CTE-NC    | high         | CTE                      |
| 10   | 70s          | M   | Soccer        | 3         | CTE-NC    | high         | CTE                      |
| 11   | 60s          | M   | Soccer        | 11        | CTE-NC    | high         | CTE                      |
| 12   | 70s          | M   | Soccer        | 6         | CTE-NC    | high         | CTE                      |
| 13   | 70s          | M   | Soccer        | 7         | ADNC      | NA           | PDD                      |
| 14   | 70s          | M   | Soccer        | 2         | ADNC      | NA           | AD                       |
| 15   | 70s          | M   | Soccer        | 3         | ADNC      | NA           | DLB                      |
| 16   | 70s          | M   | Soccer        | 8         | ADNC      | NA           | AD                       |

AD, Alzheimer’s disease; ADNC, AD neuropathologic change; CPC, clinicopathological conference; CTE, chronic traumatic encephalopathy; CTE-NC, CTE neuropathologic change; DLB, dementia with Lewy Bodies; NA, not applicable; PDD, Parkinson’s disease dementia; PMI, post-mortem interval; VaD, vascular dementia
then collated into three sets, each of 21 or 22 slides, for distribution and scoring. Nine neuropathologists with experience in the neuropathological assessment of neurodegenerative disease and co-investigators on the Collaborative Neuropathology Network Characterising Outcomes of TBI (CONNECT-TBI) programme [44] participated in assessing these digital slide sets for pathology (RF, LNH, DI, CDK, JK, GGK, AN, DPP, DSP). Participating neuropathologists were blinded not only to case related information (such as demographics, original integrated diagnosis) for each slide, but also to the antibody used and the primary aims of study. Information provided to each participating neuropathologist at recruitment described this study as an exercise exploring consistency in reporting CTE-NC, with no information that the slide sets for review contained multiple consecutive sections from individual cases stained for a panel of tau antibodies.

To access each slide set participants received a Uniform Resource Locator (URL) weblink which directed them to a Research Electronic Data Capture (REDCap) portal wherein individual stained sections were presented in a series of consecutive pages, each requiring a response to be completed before advancing to the next stained section and response page. Each response page included a unique URL link to the appropriate stained section on the Hamamatsu server, together with the response questions. After review of each digital section, participating neuropathologists were asked:

1. Would you classify this case as CTE? (select yes/no)
2. From 0–100%, how confident are you in your rating? (using slide bar, select rating from 0–100%)

Instruction on criteria for CTE-NC recognition was provided with reference to the original published consensus [37]. Neuropathologists evaluated each slide set independently, at their own pace. Once responses had been submitted for a scanned tissue section, progress to the next was automatic, with no ability to navigate backwards to previous sections. Further, complete responses for each slide set were required before the URL linking to the next slide set was released. For each case and stain, the cut-off set for consensus required that 75% or more of reviewers were in agreement, in line with the Royal College of Pathologists guidance for a diagnostic External Quality Assessment scheme [11].

Following completion of data capture for the original three slide sets, refined consensus criteria were published by the National Institute of Neurological Disorders and Stroke (NINDS) consensus panel suggesting neuronal tau pathology alone would be sufficient for recognition of CTE-NC, rather than a requirement that both neuronal and astroglial pathology are present, as described in the original consensus criteria [4]. To accommodate this revision, a further slide set was circulated. This fourth slide set contained 21 sections which had been assessed in the previous three circulations, but which were re-anonymised and re-randomised. These 21 slides were selected on review of data from the original circulations 1 to 3 to include 3R and GT-38-stained sections from the five cases in which there was 100% consensus in recognition of CTE-NC and three cases returning the lowest consensus in recognition of CTE-NC in PHF-1-stained sections, with the remaining slides randomly selected PHF-1 stained sections from among the consensus recognised CTE-NC cases from the first review screening. The same REDCap evaluation process was employed, with the additional instruction to the participating neuropathologists to review this final slide set using updated consensus criteria. The neuropathologists remained blind to all demographic and diagnostic information. Again, reviewers were unaware that multiple sections were included from individual cases, that differing antibodies had been applied and that this supplemental slide set was derived from the initial circulations.

### Statistical analysis
Non-parametric receiver operating characteristics (ROC) analyses were used to evaluate accuracy of rating CTE-NC. The area under the ROC curve (AUC) was calculated to assess rater accuracy of the slide set overall and separately by antibody. AUC values were interpreted as 1.0 = perfect, > 0.9 = outstanding, 0.8–0.89 = excellent, 0.7–0.79 = acceptable, 0.51–0.69 = poor, 0.5 = no discrimination [14, 18]. AUC equivalence tests were used to assess whether rater accuracy varied by stain. We also estimated whether sensitivity and specificity could be increased if two stains were applied in parallel, where a positive result with either stain classifies the slide as “Yes-CTE-NC” [6]. All analyses were performed using Stata/MP 16.1 (StataCorp LLC), with p-value less than 0.05 considered to indicate statistical significance.

### Results
Identification of CTE-NC is influenced by the primary antibody applied
Consistent with previous reports, sections stained with the tau antibodies employed revealed varying patterns of staining. Specifically, sections stained for PHF-1 or 4R tau typically revealed both immunoreactive neuronal and astroglial profiles, where present. In contrast, adjacent sections stained for either GT-38 or 3R tau revealed solely immunoreactive neuronal profiles (Fig. 1). Overall, using original consensus criteria, consensus recognition of CTE-NC as either absent
or present was high among reviewers (area under the curve [AUC] 0.74; 95% confidence interval [CI] 0.70 to 0.77), although this varied depending on the primary antibody used. Reflecting this, consensus recognition of CTE-NC absent or present was highest in sections stained for PHF-1 (AUC 0.85; 95% CI 0.79 to 0.92) and lowest in sections stained for 3R tau (AUC 0.52; 95% CI 0.46 to 0.59) (Fig. 2; Table 2). Indeed, where CTE-NC was present, this was recognized in just 5% of sections stained for 3R tau, compared to 75% of sections stained for PHF-1 (Table 3).

Using original consensus criteria, although recognition of pathology was highest among sections stained for PHF-1, nevertheless, there remained 4 cases with known CTE-NC among which no consensus agreement was achieved in sections stained using this antibody, with detection rates varying between 11 and 67% in these examples (Table 3). Intriguingly, in the section stained for PHF-1 with lowest detection of CTE-NC (Case 3), while this pathology was only recognised by 1 of 9 (11%) of the reviewers, there was complete consensus on the presence of CTE-NC in the adjacent section.

Fig. 1  Representative images of cortical tau pathology in a male, 80-year-old former soccer player, with known high-stage CTE-NC (Case 5), stained for various tau antibodies. In sections stained for either PHF-1 (a, e) or 4R tau (d) staining of both neuronal and astroglial profiles is present in a patchy distribution, with concentration to sulcal depths consistent with the pathognomonic lesion of CTE-NC defined in original consensus criteria. In contrast, adjacent sections from the same case stained for either 3R tau (b) or GT-38 (c) show only neuronal pathologies. Scale bars: a, 5 mm; b-e main panels, 250 µm; b-e insets 50 µm.
Review of the sections in this case revealed extensive PHF-1-immunoreactive neurofibrillary tangles, neurites and thorn-shaped astrocytes at the sulcal depth, producing a near confluent band of staining. In contrast, in the adjacent 4R section a patchier staining pattern was evident, consistent with the original consensus description of CTE-NC (Fig. 3). In the remaining three cases for which consensus recognition of CTE-NC was not achieved, these

**Table 2** Performance of each tau antibody in consensus reporting of CTE-NC as absent or present

| Tau antibody | All sections | PHF-1 | 4R | GT-38 | 3R |
|--------------|--------------|-------|----|-------|----|
| AUC (95% CI) | Sensitivity  | Specificity | PPV | NPV   |    |
| All sections | 0.74 (0.70–0.77) | 57.9 | 86.1 | 92.6 | 40.5 |
| PHF-1        | 0.85 (0.79–0.92) | 80.6 | 86.1 | 94.6 | 59.6 |
| 4R           | 0.82 (0.74–0.89) | 73.0 | 83.0 | 92.9 | 50.8 |
| GT-38        | 0.75 (0.70–0.80) | 51.9 | 97.2 | 98.2 | 40.2 |
| 3R           | 0.52 (0.46–0.59) | 15.7 | 88.9 | 81.0 | 26.0 |

AUC = area under the curve; PPV = positive predictive value; NPV = negative predictive value; GT38 vs. 4R, p = 0.140; GT38 vs. PHF-1, p < 0.005; 4R vs. PHF-1, p = 0.375; 3R vs. PHF-1, p < 0.001

from this case stained for 4R. Review of the sections in this case revealed extensive PHF-1-immunoreactive neurofibrillary tangles, neurites and thorn-shaped astrocytes at the sulcal depth, producing a near confluent band of staining. In contrast, in the adjacent 4R section a patchier staining pattern was evident, consistent with the original consensus description of CTE-NC (Fig. 3). In the remaining three cases for which consensus recognition of CTE-NC was not achieved, these

**Table 3** Proportion of reviewers reporting CTE-NC for each slide and primary antibody

| Case No | 3R | GT-38 | 4R | PHF-1 |
|---------|----|-------|----|-------|
| All sections | 28% | 57% | 74% | 79% |
| CTE-NC | All sections | 5% | 43% | 70% | 75% |
| 1 | 0 | 33% | 56% | 44% |
| 2 | 0 | 56% | 78% | 89% |
| 3 | 22% | 0 | 100% | 11% |
| 4 | 11% | 22% | 78% | 78% |
| 5 | 0 | 44% | 100% | 100% |
| 6 | 11% | 33% | 67% | 100% |
| 7 | 0 | 78% | 44% | 100% |
| 8 | 0 | 67% | 44% | 67% |
| 9 | 0 | 11% | 56% | 100% |
| 10 | 0 | 78% | 100% | 89% |
| 11 | 11% | 89% | 100% | 100% |
| 12 | 0 | 0 | 22% | 22% |

**ADNC**

| Case No | All sections | 3% | 0 | 17% | 8% |
|---------|--------------|----|---|-----|---|
| 13 | 0 | 0 | 0 | 0 |
| 14 | 0 | 0 | 56% | 11% |
| 15 | 0 | 0 | 11% | 11% |
| 16 | 11% | 0 | 0% | 11% |
showed extensive tau pathologies at the sulcal depths, with no improvement in consensus recognition of CTE-NC in adjacent sections stained for the remaining tau antibodies.

**Revised consensus criteria do not improve consensus in CTE-NC recognition**

Immediately following primary section reviews and data collection, revised consensus criteria for the neuropathological assessment of CTE were published, placing greater emphasis on neuronal p-tau pathology, “with or without glial tau in thorn-shaped astrocytes” as sufficient for recognition of the pathognomonic lesion of CTE-NC [4]. Review of a supplemental slide set containing representative stained sections which had been assessed in the primary reviews, but under instruction to apply revised criteria for CTE-NC, resulted in no improvement in recognition of diagnostic pathology, either in neuronal specific or broader primary antibody preparations. Specifically, in sections stained with 3R, GT38, or PHF-1 overall recognition of CTE-NC did not differ between primary and secondary reviews ($p = 0.766$) (Table 4).

**Discussion**

Herein we present an analysis of unbiased, blinded reviews of cortical tau pathologies in chronic traumatic encephalopathy neuropathologic change (CTE-NC) employing a panel of antibodies revealing either solely neuronal or mixed neuronal and astroglial pathologies. In so doing, observations in our cohort demonstrate that recognition of the pathognomonic cortical pathology of CTE-NC is optimised by visualisation of both neuronal and astroglial tau pathologies. Specifically, in cortical tissue sections stained with antibodies revealing mixed neuronal and astroglial tau pathologies (PHF-1 or 4R tau), accurate consensus recognition of CTE-NC was high among expert neuropathology reviewers. In contrast, where adjacent sections from the same cases were stained for antibodies revealing solely neuronal tau pathology (GT-38 or 3R tau), accurate recognition of CTE-NC was considerably impaired; in the case of 3R tau, it was no better than chance. Importantly, these findings remained when refined NINDS criteria for neuropathological recognition of CTE-NC were employed, suggesting neuronal tau pathology alone might be insufficient in defining the pathognomonic lesion.

While descriptions of the pathology of CTE first emerged over half a century ago in reports of dementia pugilistica of boxers [7], only in the last decade have consensus criteria for the neuropathological evaluation of cases with suspected CTE and its recognition emerged [4, 37]. In the first iteration of these consensus criteria the contributing pathologists reviewed 10 cases with known high-stage CTE-NC selected from a single archive’s holdings, alongside 15 cases of wider tauopathies. Following review and discussion, the panel defined

---

**Fig. 3** Representative images of cortical tau pathology in Case 3, a 73-year-old male, former rugby player, with known high-stage CTE-NC from the original diagnostic evaluation. In the section stained for PHF-1 extensive, confluent cortical staining is present within neuronal and astrocytic profiles with no particular cortical distribution discernible (a, c). In contrast, in an adjacent section stained for 4R tau, patchy cortical staining is evident, showing concentration to the depths of cortical sulci, consistent with the pathognomonic lesion of CTE-NC (b, d). Scale bars: a-b 1 mm; c-d main panels, 250 µm; c-d insets, 50 µm
the pathognomonic lesion of CTE-NC as consisting of ‘p-tau aggregates in neurons, astrocytes, and cell processes around small vessels in an irregular pattern at the depths of cortical sulci’ [37]. Thereafter, in a second consensus review process the panel examined a further 16 cases with low (n=4; two of which after consensus review were deemed to show no diagnostic pathology) or high (n=12) stage CTE-NC, alongside 3 of the CTE-NC cases assessed in the original consensus review and 10 cases with wider, non-CTE-NC pathologies [4]. Following this second review process, the expert panel recommended the criteria for recognition of the pathognomonic cortical lesion of CTE-NC be refined, with the requirement for p-tau pathology in both neurons and astrocytes modified to place greater emphasis on the presence of p-tau in neurons alone being sufficient, ‘with or without thorn shaped astrocytes’ [4]. This refinement to the criteria for recognition of the pathognomonic lesion of CTE-NC, therefore, implied that a diagnosis can be made in the absence of p-tau immunoreactive astrocytes. Notably, however, both these consensus review processes employed subjective, qualitative methodologies, with review of pre-selected cases from a single archive’s wider holdings. Employing unbiased, blinded review by multiple expert neuropathologists, some of whom also participated in the NINDS consensus review panel, of consecutive cases donated to the Glasgow TBI Archive, our data show that in preparations where only neuronal p-tau profiles were stained, recognition of CTE-NC was impaired. In contrast, where both neuronal and astroglial tau pathologies were revealed, consensus recognition of CTE-NC was highest.

Various approaches for staging of CTE-NC have been proposed, although these have largely either not been subject to independent evaluation [40] or have failed to perform under consensus review [4, 36]. Thus, at present, the working recommendation is that a dichotomous approach to staging is adopted, with CTE-NC reported as either low- or high-stage disease [4]. Notably, just 2 cases in this current study and a further 2 cases in the NINDS consensus reviews were considered low-stage disease. Of the low-stage cases evaluated in this study, one of these (Case 2) showed clear consensus for CTE-NC in stains for 4R or PHF-1 but failed to be recognised as such in sections stained for 3R or GT-38. The second low-stage case (Case 1) failed to achieve consensus for CTE-NC in any of the stained sections. Although just two case observations, these data might be interpreted as suggesting that even in low stage disease, the presence of astroglial pathology aids recognition of CTE-NC. Nevertheless, it must be acknowledged that current published evaluations of CTE-NC are biased towards higher stage disease, with a total of just 4 low-stage cases reviewed across this study and the NINDS consensus processes. As such, it remains possible that with greater case experience, low-stage CTE-NC might still be defined as localised to solely neuronal or, conceivably, solely astroglial profiles.

The current study supports the importance of selection of an appropriate tau antibody to reveal a broad spectrum of pathology in the evaluation of CTE-NC. Previous work has shown that neuronal and astroglial tau pathologies in CTE-NC echo tau isoforms and immunophenotypes encountered in aging and Alzheimer’s disease (AD) [2]. Specifically, thorn-shaped astrocytes of CTE-NC are

Table 4  Proportion of reviewers reporting CTE-NC applying original then revised NINDS consensus criteria to the same stained section

| Case No | 3R Primary review | Secondary review | GT-38 Primary review | Secondary review | PHF-1 Primary review | Secondary review |
|---------|-------------------|------------------|---------------------|------------------|----------------------|------------------|
| 1       | 0                 | 11%              | 33%                 | 44%              | –                    | –                |
| 2       | –                 | –                | –                   | –                | 89%                  | 67%              |
| 3       | 22%               | 22%              | 0                   | 11%              | –                    | –                |
| 4       | –                 | –                | –                   | –                | 78%                  | 89%              |
| 5       | 0                 | 11%              | 44%                 | 11%              | –                    | –                |
| 6       | 11%               | 22%              | 33%                 | 33%              | 100%                 | 100%             |
| 7       | 0                 | 11%              | 78%                 | 33%              | –                    | –                |
| 8       | –                 | –                | –                   | –                | 67%                  | 78%              |
| 9       | 0                 | 0                | 11%                 | 11%              | –                    | –                |
| 10      | –                 | –                | –                   | –                | 89%                  | 100%             |
| 11      | 11%               | 33%              | 89%                 | 89%              | –                    | –                |
| 12      | 0                 | 0                | 0                   | 0                | –                    | –                |
ARTAG, while on the other hand it might suggest that astroglial pathologies of CTE-NC and cortical areas [30, 31]. On one hand, these observations raise the possibility of underlying CSF- or blood–brain barrier (BBB) disruption driving the observed pathology. Notably, although subjective assessments of these pathologies in CTE-NC are widely reported as showing both neuronal and astroglial pathologies localised to the sulcal depths, including those of consensus reviews [4, 37], formal quantitative evaluation demonstrates primarily the astroglial profiles show specific concentration at this site, with the neuronal pathology showing only limited sulcal concentration, similar to that of AD [1]. Taken together with our current observations, these studies suggest that while neuronal p-tau in CTE-NC might be indistinguishable from that of aging and AD, both in sulcal distribution and immunophenotype using currently available antibodies for diagnostic practice, the astroglial pathology of CTE-NC shows distinctive cortical distribution. Therefore, the constant presence of astrocytic p-tau pathology in CTE-NC in a distinctive pattern and distribution supports its inclusion as required (i.e. pathognomonic) pathology alongside neuronal tau to facilitate the neuropathological diagnosis of CTE-NC.

The contribution of thorn-shaped astrocytes to recognition of CTE-NC revealed in this study raises the intriguing potential that, rather than incidental pathology of limited importance, the observed astrocytic p-tau pathology might be both specific to prior exposure to TBI and might provide evidence of an underlying, driving neurodegenerative process. Notably, early descriptions of ARTAG documented pathology in the medial temporal lobe, with more recent reports noting a resemblance of ARTAG to CTE-NC in some cases [30]. Importantly, thorn-shaped astrocytes in the depths of cortical sulci are rare in normal ageing [10] but can be seen in Guam amyotrophic/parkinsonism-dementia complex [29]. The distribution of ARTAG in many of these descriptions raises the possibility of underlying CSF- or blood–brain barrier disruption driving the observed pathology [28, 30]. Intriguingly, evidence of extensive, widespread blood–brain barrier (BBB) disruption has been observed following single moderate or severe TBI, which can persist even many years after injury [16]. Similarly, evidence of widespread BBB disruption has also been reported after repetitive mild TBI in humans [8], and as a pathological consequence of mild TBI in experimental models [24]. Mathematical modelling indicates that a local (i.e. mechanical) inducing factor might contribute to the development of subpial thorn-shaped astrocytes in cortical areas [30, 31]. On one hand, these observations suggest that BBB dysfunction is a common event in the pathogenesis of astroglial pathologies of CTE-NC and ARTAG, while on the other hand it might suggest that local mechanical factors contribute to the focal cortical ARTAG of aging or other conditions showing overlap with the pathogenesis of CTE.

In summary, our data demonstrate the presence of both neuronal and astroglial tau pathologies facilitates recognition of CTE-NC, with its detection less consistent when neuronal tau pathology alone is visible. The combination of both glial and neuronal pathologies, therefore, may be required for detection of CTE-NC. In addition, in cases where there is overwhelming cortical p-tau pathology, application of the 4R tau isoform antibody might aid in revealing CTE-NC. While further studies are required to continue the process of refinement of our understanding of the specific pathologies of CTE, including those of earlier stages in disease, this work further underlines the value of unbiased, blinded review and analysis over subjective methodologies in evaluating patterns of disease.

**Disclosure**

The information, conclusion and opinions expressed herein do not necessarily represent the official position or policy of, nor should any official endorsement be inferred on the part of, the Uniformed Services University of the Health Sciences, the US Department of Defense, the Veterans Administration, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc or any other US Government agency.

**Abbreviations**

AD: Alzheimer’s disease; ADNC: Alzheimer’s disease neuropathologic change; ARTAG: Aging related tau astrogliopathy; AUC: Area under the curve; BBB: Blood–brain barrier; CONNECT-TBI: Collaborative Neuropathology Network Characterising Outcomes of TBI; CTE: Chronic traumatic encephalopathy; CTE-NC: Chronic traumatic encephalopathy neuropathologic change; DAB: 3,3’-Diaminobenzidine; EDTA: Ethylenediaminetetraacetic acid; NINDS: National Institute of Neurological Disorders and Stroke; PART: Primary age-related tauopathy; P-tau: Hyperphosphorylated tau; REDCap: Research Electronic Data Capture; ROC: Receiver operating characteristics; TBI: Traumatic brain injury; URL: Uniform resource locator; 3R: 3 Microtubule-binding domain repeats; 4R: 4 Microtubule-binding domain repeats.

**Acknowledgements**

The authors wish to thank the brain donors and their families, without whom this research would be impossible.

**Author contributions**

KAA, WS, AB, EBL, and DAW conceived of the study, and designed and performed data analysis. RF, LNH, DI, CDK, JK, GGK, AN, DPP, and DSP participated in slide evaluations. KAA and AB wrote the first manuscript draft. All authors reviewed and commented on the final manuscript draft.

**Funding**

This work was supported by funding from: the National Institutes of Health, National Institute of Neurologic Disorders and Stroke, US (award numbers U54NS113322, R01NS03814); the National Institutes on Aging, US (award numbers P30AG072979, P01AG066597); and the Nancy and Buster Alvord Endowment.
Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions